Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FURIN | P09958 | 6/20 | 0.40 |
| ▸ | BACE1 | P56817 | 7/20 | 0.39 |
| ▸ | CTSD | P07339 | 3/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6117674 | 1.00 | FURIN (0.40) | FURINBACE1CTSDOPRL1 | |
| SCHEMBL676551 | 0.89 | BACE1 (0.45) | FURINBACE1CTSD | |
| SCHEMBL30361652 | 0.89 | BACE1 (0.45) | FURINBACE1CTSDOPRL1 | |
| SCHEMBL3203608 | 0.89 | BACE1 (0.39) | FURINBACE1CTSDOPRL1 | |
| SCHEMBL3209141 | 0.84 | FURIN (0.38) | FURIN | |
| SCHEMBL32690572 | 0.81 | BACE1 (0.43) | FURINBACE1CTSD | |
| SCHEMBL7922664 | 0.81 | CTSD (0.41) | FURINBACE1CTSD | |
| SCHEMBL7922670 | 0.81 | CTSD (0.41) | FURINBACE1CTSD | |
| SCHEMBL31201162 | 0.79 | BACE1 (0.51) | FURINBACE1CTSD | |
| SCHEMBL29366972 | 0.78 | GSR (0.41) | FURIN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017633-B2 | Administering [3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)benzamide; hypertension, hyperlipidemia, hyperuricemia, gout and hypercoagulability | NYCOMED GMBH (DE) | 2011-09-13 | — | — | US | disclosed |
| US-20080214625-A1 | Roflumilast for the Treatment of Diabetes Mellitus | KONINKLIJKE HILIPS ELECTRONICS, N.V. (NL) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214625-A1 | Roflumilast for the Treatment of Diabetes Mellitus | NOS3, PLAT, PTGIS | FURIN 1759/4885BACE1 2701/4885CTSD 615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.